Shen Jie, Yang Dashuai, Ding Youming
Department of Hepatobiliary Surgery, Renmin Hospital of Wuhan University, Wuhan 430060, China.
Cancers (Basel). 2022 Oct 13;14(20):5018. doi: 10.3390/cancers14205018.
HCC, one of the most common and deadly cancers worldwide, develops from hepatocytes and accounts for more than 90% of primary liver cancers. The current widely used treatment modalities are far from meeting the needs of liver cancer patients. CAR-T cell therapy, which has recently emerged, has shown promising efficacy in lymphoma and hematologic cancers, but there are still many challenges to overcome in its application to the clinical treatment of HCC, including osmotic barriers, the inhibition of hepatocellular carcinoma microenvironment activity, the limited survival and killing ability of CAR-T cells, and inevitable side effects, among others. As a result, a number of studies have begun to address the suboptimal efficacy of CAR-T cells in HCC, and many of these schemes hold good promise. This review focuses on advances in the past five years aimed at promoting the efficacy of CAR-T cell therapy for treatment of HCC.
肝癌是全球最常见且致命的癌症之一，由肝细胞发展而来，占原发性肝癌的90%以上。目前广泛使用的治疗方式远远无法满足肝癌患者的需求。最近出现的嵌合抗原受体T细胞（CAR-T）疗法在淋巴瘤和血液系统癌症中显示出了有前景的疗效，但在其应用于肝癌临床治疗方面仍有许多挑战需要克服，包括渗透屏障、肝细胞癌微环境活性的抑制、CAR-T细胞有限的存活和杀伤能力以及不可避免的副作用等。因此，一些研究已开始着手解决CAR-T细胞在肝癌中疗效欠佳的问题，其中许多方案颇具前景。本综述聚焦于过去五年中旨在提高CAR-T细胞疗法治疗肝癌疗效的进展。
